Vladislav Griniuk

Dr. Vladislav Griniuk

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
KSK. V. Shevtsova
K. V. Shevtsova
DRD. O. Rozhkov
D. O. Rozhkov
DGD. A. Grishina
D. A. Grishina
VGVladislav Griniuk
Vladislav Griniuk
VZV. V. Zakharov
V. V. Zakharov
VPV. A. Parfenov
V. A. Parfenov
Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD.

19 April 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DGD. A. Grishina
D. A. Grishina
NKN. A. Khayalieva
N. A. Khayalieva
VGVladislav Griniuk
Vladislav Griniuk
ATA. Yu. Tyurina
A. Yu. Tyurina
The use of biological markers for Alzheimer's disease (AD) allows diagnosis at the stage of moderate cognitive impairment and atypical course of the disease. We present two clinical cases of patients with posterior cortical atrophy (PCA), characterized by progressive impairment of visual and spatial functions due to atrophy of the parietal and occipital lobes of the brain. A differential diagnosis was made between AD, corticobasal degeneration and other diseases in which PCA syndrome occurs. In the cases observed, the patients showed a significant decrease in the level of beta-amyloid in the cerebrospinal fluid, which allowed the diagnosis of AD to be made. Clinical manifestations, diagnosis and treatment of PCA syndrome are discussed. At present, the diagnosis of AD at the stage of moderate cognitive impairment and mild dementia is of practical importance, as anti-amyloid therapy can prevent the progression of AD.

24 October 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DRD. O. Rozhkov
D. O. Rozhkov
KSK. V. Shevtsova
K. V. Shevtsova
VGVladislav Griniuk
Vladislav Griniuk
VPVladimir Parfenov
Vladimir Parfenov
Objective: non-interventional study ELBRUS (Etoricoxib in the Treatment of Back Pain) was conducted to investigate the efficacy and safety of daily administration of Rixia® (Etoricoxib) 60 mg per day in patients with chronic non-specific low back pain (CNSLBP).Patients and methods. The study included 50 patients (31 women and 19 men, mean age 54.3±16.8 years) with CNSLBP. Educational conversation, cognitive therapy, regular therapeutic exercises, identification and treatment of comorbidities were conducted. Patients received etoricoxib 60 mg once daily. Pain intensity was assessed on a 10-point numerical rating scale (NRS), pain-related disability was assessed on the Oswestry Scale (ODS), and emotional state was assessed on the Hospital Anxiety and Depression Scale (HADS).Results and discussion. The causes of CNSLBP were: in 5 (10%) patients – sacroiliac joint involvement, in 14 (28%) – lower lumbar facet joints involvement, in 3 (6%) – myofascial pain, the remaining 28 (56%) patients had a combination of several reasons. As a result of complex treatment, the intensity of pain at rest decreased on average from 4.0±2.5 to 1.4±1.3 points, while moving – from 6.6±1.9 to 2.8±1.8 points, at night – from 2.7±2 to 0.7±0.9 points according to the NRS, disability – from 39±18.9 to 19.9±14.6% according to the ODS, the severity of anxiety – from 6.5±3.9 to 3.3±2.4 points and depression from 5.0±3.7 to 3.1±2.9 points according to HADS (p˂0.001). The duration of treatment was 14.14±3.6 days on average. No adverse events were observed during treatment with etoricoxib.Conclusion. The efficacy and safety of etoricoxib in the complex therapy of patients with CNSLBP was noted.

21 June 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
SNSh. R. Nabiev
Sh. R. Nabiev
SDS. A. Dzhukkaeva
S. A. Dzhukkaeva
MAM. Sh. Asvedov
M. Sh. Asvedov
DPD. E. Prokhorov
D. E. Prokhorov
EPE. V. Popova
E. V. Popova
OVOlga Voskresenskaya
Olga Voskresenskaya
Objective: to determine the sensitivity and specificity of method of determining the concentration of immunoglobulin free light chains (FLCs) in cerebrospinal fluid (CSF) in the diagnosis and differential diagnosis of multiple sclerosis (MS).Material and methods. 80 patients participated in the study. The main group consisted of 54 patients diagnosed with MS according to the 2017 McDonald criteria. The comparison group (n=26) comprised patients with other diseases of the nervous system. An enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of FLCs (kappa- and lambda-chains) in the CSF.Results. In the group of patients with MS, an increase in the concentration of free kappa-chains (к-FLCs) in the CSF was found compared to the comparison group (p<0.001). With an increase in the concentration of κ-FLCs, a decrease in the sensitivity and an increase in the specificity of the method for the diagnosis of MS was observed. The к-FLCs cut-off value of 0.17 μg/ml had a sensitivity of 68.5 % and a specificity of 92.3 %. The cut-off value of 0.22 μg/ml had a sensitivity of 59.3 % and a specificity of 100 %. The concentrations of lambda-FLCs in the CSF in the MS group and in the comparison, group did not differ significantly (p=0.1).Conclusion. The results obtained indicate an increase in the concentration of к-FLCs in the CSF of MS patients. This biomarker showed a high specificity for this pathology. However, further development of optimal thresholds is required to clarify the diagnostic value of CSF к-FLCs concentration in MS patients.

29 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
DGD.A. Grishina
D.A. Grishina
VGVladislav Griniuk
Vladislav Griniuk
MNM.R. Nodel
M.R. Nodel
ATA.YU. Tyurina
A.YU. Tyurina
EME.A. Mkhitaryan
E.A. Mkhitaryan
YCYa.I. Chervyakova
Ya.I. Chervyakova
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). Most often, CBS is associated with corticobasal degeneration (CBD) or Alzheimer’s disease (AD). In some cases, differential diagnosis between these diseases based only on clinical and neuroimaging data is challenging. Biological markers for AD may prove crucial in establishing an accurate diagnosis. Two cases of patients with CBS and Alzheimer-type memory disorders are presented. Asymmetric cortical atrophy was detected by brain MRI. In the presented cases, patients showed a significant decrease in the Aβ42 levels in the cerebrospinal fluid, which helped to establish the diagnosis of AD. The issues of differential diagnosis of BSC associated with CBS and AD are discussed. The use of biomarkers for atypical clinical manifestations of AD may help to make a diagnosis early. Accurate diagnosis of AD is necessary both for the timely administration of available symptomatic drugs and for determining the indications for pathogenetic anti-amyloid therapy.

3 October 2022 in Russian neurological Journal
Verified
Journal Article
Closed access
PDF file
SMS. A. Mamykina
S. A. Mamykina
OVOlga Voskresenskaya
Olga Voskresenskaya
TST. E. Shmidt
T. E. Shmidt
VGVladislav Griniuk
Vladislav Griniuk
Isolated oculomotor disorders caused by central nervous system damage are quite rare. As a rule, they are combined with other signs of cerebral trunk damage. A clinical case with the focus of amyelination in the cerebral trunk area, which manifests itself in the form of bilateral horizontal gaze palsy in the absence of other focal neurological symptoms is presented. A complete regression of oculomotor disorders was observed against the background of glucocorticosteroid therapy. A differential research was carried out among amyelinating, ophthalmic, endocrinologic diseases, ANCA-associated vasculitis (AAV).